Dose-dense intensified sequential versus conventionally-dosed anthracycline and taxane-containing neoadjuvant therapy in patients with inflammatory breast cancer
Background: This post-hoc analysis aimed to compare an intense dose-dense sequential chemotherapy (DD-CT) and a conventionally-dosed chemotherapy (CD-CT) in the neoadjuvant AGO-1 study, focusing on the subgroup with inflammatory breast cancer (IBC). Patients and Methods: Out of 668 randomised patien...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
June 22, 2012
|
| In: |
Anticancer research
Year: 2012, Volume: 32, Issue: 8, Pages: 3539-3545 |
| ISSN: | 1791-7530 |
| Online Access: | Verlag, Volltext: http://ar.iiarjournals.org/content/32/8/3539
|
| Author Notes: | N. Ditsch, A. Vodermaier, A. Hinke, S. Burghardt, M. Lenhard, B. Löhrs, B. Toth, F. Von Koch, S. Kahlert, I. Bauerfeind, G. E. Konecny, S. Loibl, G. Von Minckwitz, M. Untch |
| Summary: | Background: This post-hoc analysis aimed to compare an intense dose-dense sequential chemotherapy (DD-CT) and a conventionally-dosed chemotherapy (CD-CT) in the neoadjuvant AGO-1 study, focusing on the subgroup with inflammatory breast cancer (IBC). Patients and Methods: Out of 668 randomised patients, 101 patients presented with IBC. Patients received epirubicin followed by paclitaxel every 2 weeks (DD-CT) or simultaneously every 3 weeks (CD-CT). Results: No differences in pathological complete response rates were observed [odds ratio (OR)=1.27, p=0.33]. Most patients were scheduled for mastectomy before starting therapy; however, in 21.7% breast-conserving surgery was performed. Disease-free survival rates [Hazard Ratio (HR)=0.65; p=0.597] and overall survival rates (HR=1.40; p=0.327) were similar for both treatment arms. Patients with breast-conserving surgery had a significantly better outcome than patients treated with mastectomy (disease-free survival: HR=0.41; p=0.034 and overall survival: HR=0.09; p=0.003). Conclusion: Patients with IBC benefited not from DD-CT but from breast-conserving surgery after neoadjuvant chemotherapy. |
|---|---|
| Item Description: | Gesehen am 18.04.2018 |
| Physical Description: | Online Resource |
| ISSN: | 1791-7530 |